Site search
2956 results for '' found
https://app.prompt.org.au/download/265825?code=e31cc5bf-5eba-4500-863c-cdd302ce2374
Wellness_Centre_Newsletter_July_2026.pdf
Medly Research on International Implementation Success and Clinical Effectiveness [Medly-RISE] (Trial Not Registered)
Medly Research on International Implementation Success and Clinical Effectiveness [Medly-RISE] (Trial Not Registered)
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with
/
An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures (NCT07141329)
An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures (NCT07141329)
/
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed with Epilepsy (NCT07238868)
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed with Epilepsy (NCT07238868)
/
An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD+ CLL patients after first-line venetoclax + obinutuzumab [MOONSHOT] (ACTRN12625000387426)
An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD+ CLL patients after first-line venetoclax + obinutuzumab [MOONSHOT] (ACTRN12625000387426)
/
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial (NCT07430267)
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial (NCT07430267)
/
Patient Stratification and Monitoring of ACTAIR® Treatment Efficacy Using New Objective Immune Markers (Trial Not Registered)
Patient Stratification and Monitoring of ACTAIR® Treatment Efficacy Using New Objective Immune Markers (Trial Not Registered)
/
A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT06966401)
A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT06966401)
/